BiotechTube

Firmonertinib + EGFR-TKI inhibitor based on investigator's choice

Phase 3Recruiting
0 views this week 0 watching⚡ Active🔬Featured in Small-Cap Pipeline Watch
Interest: 41/100
41
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Non-Small-Cell Lung Cancer

Conditions

Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer, EGFR P-Loop and Alpha C-Helix Compressing, EGFR PACC, EGFR Uncommon Mutations

Trial Timeline

Dec 17, 2025 → Dec 1, 2030

NCT ID
NCT07185997

About Firmonertinib + EGFR-TKI inhibitor based on investigator's choice

Firmonertinib + EGFR-TKI inhibitor based on investigator's choice is a phase 3 stage product being developed by ArriVent Biopharma for Non-Small-Cell Lung Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07185997. Target conditions include Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer.

What happened to similar drugs?

7 of 20 similar drugs in Non-Small-Cell Lung Cancer were approved

Approved (7) Terminated (6) Active (9)
✅Gefitinib + DocetaxelAstraZenecaApproved
✅PembrolizumabMerckApproved
✅zoledronic acidNovartisApproved
✅AtezolizumabRocheApproved
✅Erlotinib + ChemotherapyRocheApproved
✅LorlatinibPfizerApproved
✅Pemetrexed + ErlotinibHikma PharmaceuticalsApproved

Hype Score Breakdown

Clinical
17
Activity
15
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07185997Phase 3Recruiting

Competing Products

20 competing products in Non-Small-Cell Lung Cancer

See all competitors
ProductCompanyStageHype Score
pemetrexed + erlotinibEli LillyPhase 2
35
6-Thio-2'-Deoxyguanosine + CemiplimabMAIA BiotechnologyPhase 2
32
pemetrexed + cisplatinEli LillyPhase 2
27
CetuximabEli LillyPhase 1
29
LY2875358 + ErlotinibEli LillyPhase 2
35
AdjuvantInsight Molecular DiagnosticsPre-clinical
8
Enzastaurin HCLEli LillyPhase 2
35
CAB-AXL-ADC + PD-1 inhibitorBioAtlaPhase 2
25
ALIMTA + CarboplatinEli LillyPhase 2
35
LazertinibYuhanPhase 1/2
32
CS-7017 + ErlotinibDaiichi SankyoPhase 1
29
Datopotamab Deruxtecan (Dato-DXd)Daiichi SankyoPhase 1/2
36
Raludotatug Deruxtecan + Ifinatamab Deruxtecan + Docetetaxel + 5-hydroxytryptamine subtype 3 receptor antagonist + Neurokinin-1 receptor antagonist + CorticosteroidDaiichi SankyoPhase 2
42
Pembrolizumab + Carboplatin + Paclitaxel + Pemetrexed + Vibostolimab + Boserolimab + MK-4830 + MK-0482 + Ifinatamab Deruxtecan (I-DXd) + HER3-DXdDaiichi SankyoPhase 1/2
39
CS-7017 + Carboplatin + PaclitaxelDaiichi SankyoPhase 1
29
Tivantinib + Placebo + ErlotinibDaiichi SankyoPhase 3
32
Gilteritinib + ErlotinibAstellas PharmaPhase 1/2
24
naquotinib + midazolamAstellas PharmaPhase 1
29
Tarceva + carboplatin + paclitaxelAstellas PharmaPhase 2
35
Tarceva (erlotinib HCl, OSI-774 )Astellas PharmaPhase 3
40